Amneal intros Focinvez

Amneal is launching Focinvez, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger, the company said.

Focinvez for injection is indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin, and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

[Read more: Challenges continue, but generics companies see a bright future with biosimilars]

“We continue to launch differentiated complex products that are clinically impactful,” said Sean McGowan, vice president of biosimilars and branded oncology. “This is the second ready-to-use injectable we have launched this year that offers hospitals and oncology clinics a new presentation format that can improve pharmacy efficiency. These new 505(b)(2) injectables represent a new vector of growth for our expanding injectables portfolio.”

Fosaprepitant had a market value of roughly $36 million for the 12 months ended April 2024, per IQVIA. 

[Related: Amneal touts 39 retail, injectable product launches in 2023]